

News AT A GLANCE




From generics to innovation: Indian...

► Page No. 6



Scientific infrastructure, supply-chain capability...

► Page No. 22



India's pharma future hinges on balancing...

► Page No. 25



Innovation, trust and preventive healthcare ...

► Page No. 36

iPHEX 2026: Indian pharma industry eyes \$1.4 bn export opportunities

OUR BUREAU, MUMBAI

THE Pharmaceuticals Export Promotion Council of India (Pharmexcil) has set an ambitious target of unlocking approximately USD 1.4 billion in export business opportunities through the upcoming 12th edition of iPHEX 2026, scheduled from September 7-9 at Bharat Mandapam, New Delhi. The three day exhibition and conference

arrives at a pivotal moment for India's pharmaceutical sector, which recorded a 6.8% growth in exports in Q1 FY27 compared to the same period last year.

This growth underscores India's resilience in a complex global trade environment, where supply chain disruptions, pricing pressures, and regulatory challenges continue to test exporters. Against this backdrop, iPHEX 2026 is being positioned not merely as

a trade fair but as a strategic platform to connect Indian manufacturers with international buyers, strengthen trust, and convert conversations into concrete business deals.

Scale and Scope of iPHEX 2026

The event promises to be one of the largest gatherings of pharmaceutical stakeholders in Asia. With 800+ exhibitors, 600 overseas companies, and

CONTINUED ON p2►



ENRICHING WORLD WITH
ENZYMES & PROBIOTICS!





Syngenic
BIOSCIENCE

PHARMA ENZYME

- Bromelain 600-2400 GDU
- Serratiopeptidase IP
- Trypsin Chymotrypsin Mix (6:1)
- Trypsin USP/BP
- Pancreatin USP/IP/BP/EP
- Veg Pancreatin
- Pepsin IP
- Fungal Diastase IP
- Papain IP/USP

FOOD ENZYME

- Fungal Amylase 10000 - 150000 SKB U/g
- Rennet 2000-15000 IMC U/g
- Bromelain 600-2400 CDU/g
- Lactase 2000-100000 ALU/g
- Papain 50-1000 TU/mg
- Bacterial Amylase 2000 - 50000 BAU/g
- Phospholipase 2000 - 10000 U/g
- Acid Protease 20000-600000 HUT/g
- Alkaline Protease 5000-500000 u/g
- Neutral Protease 25000-500000 u/g
- Lipase 10000-200000 FIP U/g
- Maltogenic Amylase 2000-15000 MAN U/g
- Alpha Galactosidase 1500-30000 GAL U/g
- Acid Cellulase 10000-200000 CNC U/g
- Bromelain 600-2400 GDU/g
- Neutral Cellulase 5000-50000 U/g
- Pectinase 10000-200000 U/g
- Polygalacturonase 5000-40000 PCU/g
- Xylanase 5000-200000 U/g
- Polygalacturonase 5000-40000 PGU/g
- Xylanase 5000-200000 XU/g

Pellets for Food & Nutraceutical

- Menthol Pellets
- Bacillus Coagulans Pellets
- Bacillus Clausi Pellets
- Simethicone Pellets
- Pancreatin Pellets
- Activated Charcoal Pellets
- Alpha Lipoic Acid Pellets
- Sorbitol Pellets
- Sugar Spheres
- Dried Ferrous Sulphate
- Folic Acid Pellets
- Carbonyl Iron,
- Folic Acid Pellets Blend

PROBIOTICS FOR NUTRACEUTICAL & ANIMAL FEED

- Bacillus Clausii 10-150 BN
- Bacillus Coagulans 10-200 BN
- Bacillus Subtilis 10-200 BN
- Bifidobacterium Adolescentis 10-150 BN
- Bifidobacterium Animalis 10-200 BN
- Bifidobacterium Animalis Lactis 10-150 BN
- Bifidobacterium Longum 20-200 BN
- Bifidobacterium Infantis 10-150 BN
- Enterococcus Faecium 10-200 BN
- Lactobacillus Brevis 10-200 BN
- Lactobacillus Buchneri 10-200 BN
- Lactobacillus Bulgaricus 10-300 BN
- Lactobacillus Casei 10-300 BN
- Lactobacillus Crispatus 10-100 BN
- Lactobacillus Delbrueckii 10-150 BN
- Lactobacillus Fermentum 10-300 BN
- Lactobacillus Gasseri 10-300 BN
- Lactobacillus Johnsonii 10-200 BN
- Lactobacillus Paracasei 10-400 BN
- Lactobacillus Plantarum 10-500 BN
- Lactobacillus Pentosus 10-100 BN
- Lactobacillus Sakei 10-100 BN
- Lactobacillus Salivarius 10-300 BN
- Lactobacillus Lactis 10-300 BN
- Lactobacillus GG 10-200 BN
- Pediococcus Acidilactici 10-200 BN
- Pediococcus Pentosaceus 10-150 BN
- Streptococcus Thermophilus 10-100 BN
- Streptococcus Faecium 10-100 BN
- Saccharomyces Cerevisiae 5-20 BN
- Saccharomyces Boulardii 5-20 BN

Corporate Office - 338.5 Square Point, Jahangirpura, Surat-395005

Manufacturing Unit - Plot-C1, Moti Naroili Village, NH-8, Kirm, Surat-394111 (Guj.)

SYNGENIC BIOSCIENCE LLP

+91-86900 76795 | sales@syngenicbioscience.com

www.syngenicbioscience.com








Strategies to build India's pharma regulatory and compliance ecosystem with global markets



DR. SANJAY AGRAWAL

INDIA has emerged as one of the world's most important pharmaceutical hubs, supplying medicines, vaccines, active pharmaceutical ingredients (APIs), and generic formulations to markets across the globe. Its cost competitiveness, manufacturing capabilities, scientific talent, and expanding research ecosystem have created significant opportunities for further growth. However, as pharmaceutical markets become increasingly regulated and interconnected, India's future competitiveness will depend not only on manufacturing capacity but also on the strength, consistency, and international alignment of its regulatory and compliance ecosystem.

Building a globally compatible regulatory framework requires a coordinated approach involving regulators, pharmaceutical companies, research institutions, testing laboratories, healthcare professionals, and policy-makers. The objective should be to create an ecosystem where Indian pharmaceutical products can meet stringent international requirements while maintaining affordability, quality, safety, and timely access.

Strengthening Regulatory Harmonisation

One of the most important strategies is greater harmonisation of Indian pharmaceutical regulations with internationally accepted standards. Regulatory expectations differ across markets such as the United States, European Union, United Kingdom, Japan, and emerging markets. Companies operating globally must therefore navigate multiple regulatory frameworks, documentation requirements, inspection systems, and product standards.

India can reduce this complexity by

strengthening alignment with global frameworks such as those established by the International Council for Harmonisation (ICH), World Health Organization (WHO), and other recognised regulatory bodies. Greater harmonisation of technical requirements, clinical documentation, quality standards, pharmacovigilance systems, and manufacturing expectations can make Indian approvals more compatible with international submissions.

At the same time, harmonisation should not simply mean copying foreign regulations. India needs a risk-based regulatory framework that reflects its own healthcare requirements while maintaining global credibility.

Building Stronger Quality and Manufacturing Compliance

Quality assurance must remain at the centre of India's global pharmaceutical strategy. International markets increasingly expect manufacturers to demonstrate robust Good Manufacturing Practices (GMP), data integrity, process validation, quality control, traceability, and effective corrective and preventive action systems.

Indian manufacturers should move beyond compliance as a checklist and develop a culture of continuous quality improvement. Digital quality management systems, automated monitoring, electronic batch records, real-time process analytics, and advanced laboratory technologies can strengthen manufacturing oversight.

Regulators can support this transition by expanding risk-based inspections and using data-driven approaches to identify potential quality risks. Consistent enforcement is equally important. A regulatory ecosystem gains international credibility when compliance expectations are transparent, predictable, and applied uniformly across manufacturers.

Improving Regulatory Capacity and Expertise

A globally competitive pharmaceutical ecosystem requires regulators with strong technical and scientific capabilities. Pharmaceutical regulation today extends beyond conventional manufacturing controls into areas such as biologics, biosimilars, gene therapies, cell therapies, artificial intelligence, digital health, personalised medicine, and advanced drug-delivery systems.

India should therefore invest con-

tinuously in regulatory education and specialised training. Regulatory professionals need exposure to international standards, emerging technologies, clinical research methodologies, statistical assessment, pharmacovigilance, and global inspection practices.

Collaboration between Indian regulators and international regulatory agencies can further strengthen expertise. Joint training programmes, technical exchanges, regulatory workshops, and participation in international working groups can help Indian authorities stay aligned with evolving global expectations.

Creating a Stronger Digital Regulatory Infrastructure

Digital transformation can significantly improve the efficiency and transparency of pharmaceutical regulation. India should develop integrated digital platforms through which companies can submit applications,



track regulatory processes, manage compliance documentation, report adverse events, and communicate with regulatory authorities.

Electronic submissions can reduce paperwork, improve traceability, and accelerate regulatory reviews. Artificial intelligence and advanced analytics could eventually support regulators in identifying unusual safety signals, manufacturing trends, inspection risks, and inconsistencies in submitted data.

However, digitalisation must be accompanied by strong cybersecurity, data governance, access controls, and data-integrity standards. Pharmaceutical regulatory information is highly sensitive, and the credibility of a digital ecosystem depends on maintaining the integrity and confidentiality of regulatory data.

Strengthening Clinical Research and Pharmacovigilance

India's global pharmaceutical ambitions also require stronger clinical research and post-market safety systems. Regulatory approval is only one stage of a medicine's lifecycle. Continuous monitoring is necessary to understand how products perform once they are used across diverse patient populations.

India should strengthen pharmacovigilance networks involving manufacturers, hospitals, healthcare professionals, research institutions, and regulators. Faster reporting and analysis of adverse drug reactions can help identify safety signals earlier.

Clinical research standards should also remain aligned with international ethical and scientific expectations. Improving clinical trial infrastructure, patient recruitment systems, research transparency, data quality, and institu-

tional review mechanisms can make India a more attractive destination for global pharmaceutical research and development.

Enhancing Supply Chain Traceability

Global pharmaceutical supply chains are becoming increasingly complex. Counterfeit medicines, falsified products, API shortages, quality deviations, and supply disruptions can affect patient safety as well as India's international reputation.

A stronger traceability ecosystem can help address these risks. Technologies such as barcoding, serialization, blockchain-based verification, and integrated supply-chain platforms can improve visibility from manufacturing through distribution.

India should encourage interoper-

CONTINUED ON p17▶

Strategies to build India's pharma...

CONTINUED FROM p16▶

able traceability standards that can connect domestic systems with international supply chains. Such systems would help regulators and companies identify products rapidly during recalls, investigate quality issues, and protect patients.

Supporting Small and Medium Pharmaceutical Companies

While large Indian pharmaceutical companies generally possess significant regulatory capabilities, smaller manufacturers may face challenges in meeting increasingly sophisticated global compliance requirements. High costs associated with laboratory infrastructure, digital systems, validation, regulatory expertise, and international certifications can create barriers for smaller businesses.

A stronger ecosystem should therefore provide technical guidance, training, shared testing infrastructure, regulatory support programmes, and access to compliance expertise for smaller manufacturers. Industry associations and specialised institutions can play an important role in helping these companies understand international requirements.

Supporting SMEs is particularly important because India's pharmaceutical ecosystem is broad and geographically distributed. Raising compliance standards across the entire industry will strengthen India's reputation as a reliable global supplier.

Promoting Regulatory Cooperation and Mutual Recognition

India can further strengthen its position by expanding regulatory cooperation with major pharmaceutical markets. Mutual recognition arrangements, information-sharing agreements, joint inspections, and reliance mechanisms can reduce duplication and improve regulatory efficiency where appropriate.

Greater cooperation does not mean lowering standards. Instead, it allows trusted regulatory authorities to rely on assessments or inspections al-

ready conducted by another competent authority, reducing unnecessary duplication while maintaining pa-

tient-safety safeguards.

Such mechanisms could be particularly valuable for Indian manufactur-

ers seeking simultaneous access to multiple international markets.

CONTINUED ON p19▶



Shreenath Chemicals

Manufacturer & Exporter of Bulk Drugs, Intermediates & Fine Chemicals

Since 1989

ABOUT US

37+

YEARS OF EXPERIENCE

650+

CUSTOMERS SERVED

08+

PRODUCT RANGE

07+

CORE TEAM MEMBERS

OUR CERTIFICATIONS



WHO GMP



(for Manufacturing & Trading)



HALAL



DAR



ICS



JAS-ANZ

ISO 9001 : 2015 (Quality Management System)

ISO 14001 : 2015 (Environmental Management System)

ISO 45001 : 2018 (Occupational Health and Safety Management System)

OUR PRODUCTS RANGE

Choline Salts

Ferric Salts

Calcium Salts

Amino Acids

Vitamins

Drug Intermediates

EDTA Salts

Ammonium Citrates

VIEW OUR PRODUCT LIST



CONTACT US

For India Business:
Email Id: sales.shreenath@gmail.com

For International Business:
Email Id: exports.shreenath@gmail.com

H.O.: A/711-712, Crystal Plaza Premises Co-op. Soc. Ltd.,
New Link Road, Andheri (W), Mumbai - 400053, Maharashtra, India.

Strategies to build India's pharma...

CONTINUED FROM p17►

Creating a Culture of Compliance

Ultimately, regulations are effective only when compliance becomes embedded within organisational culture. Pharmaceutical companies need to view regulatory compliance not as a cost or administrative requirement but as a fundamental component of product quality and patient safety.

Boards and senior management should establish clear accountability for quality and compliance. Employees across manufacturing, research, supply chain, sales, and quality functions should receive regular training. Internal audits, whistleblower mechanisms, data-integrity controls, and transparent reporting systems can further strengthen organisational accountability.

A proactive compliance culture also reduces the risk of costly regulatory observations, product recalls, export restrictions, and reputational damage.

Conclusion

India's pharmaceutical industry has the scale and capabilities to remain a major force in global healthcare. The next phase of growth, however, will depend increasingly on regulatory credibility rather than manufacturing capacity alone. India needs an ecosystem that combines globally harmonised standards, strong regulatory institutions, digital infrastructure, advanced quality systems, robust pharmacovigilance, supply-chain traceability, and a culture of continuous compliance.

The goal should be to make regulatory excellence a competitive advantage for Indian pharmaceuticals. By strengthening collaboration between government, regulators, industry, academia, healthcare institutions, and international partners, India can build a regulatory ecosystem that supports innovation while protecting patient safety.

A globally aligned regulatory framework will not only help Indian pharmaceutical companies enter and sustain their

presence in international markets; it will also strengthen trust in the quality, safety, and reliability of medicines manufactured in India. In the long

term, regulatory excellence can become one of the strongest foundations for India's ambition to be a trusted global pharmaceutical leader.

(The author is a Leading Pharmaceutical Consultant and Editor-in-Chief of IJMToday. Email- www.dr.sanjayagrawal.in)

 PANCHSHEEL ORGANICS LTD.	
137 Hubtown Solaris, Prof. N.S.Phadke Road Opp. Tell Gally, Andheri East, Mumbai-400069.	
TEL: +91-22-68634200/4212/4213/4214/4218	
Email : poltd@panchsheelorganics.in Website : www.panchsheelorganics.com / www.panchsheelorganicsltd.com	
ACTIVE PHARMA INGREDIENTS PRODUCT LIST	
ADENOSINE	IMIPRAMINE HCL / PAMOATE
ADRENALINE BITARTRATE	KETOPROFEN
NORADRENALINE BITARTRATE	LAMOTRIGINE
ALLYLESTRENOL	LITHIUM CARBONATE
AZATHIOPRINE	LOMEFLOXACIN HCL
AZELAIC ACID (MICRONISED)	L-THYROXINE SODIUM
BACLOFEN	MERCAPTOPYRINE
BISOPROLOL FUMARATE	METHYLCOBALAMIN 5% , 10%
BRIMONIDINE TARTRATE	MUPIROCI
BUPROPION HCL	MYCOPHENOLATE MOFETIL
BUSPIRONE	NADIFLOXACIN
BUPIVACAINE	NAPHAZOLINE HCL /NITRATE
CARBAMAZEPINE	NEPAFENAC
ESLICARBAZEPINE ACETATE	NEOSTIGMINE METHYL SULFATE /BROMIDE
OXCARBAZEPINE	OLOPATADINE
CARVEDILOL	OXYMETAZOLINE HCL
CARBOCISTEINE	PYRIDOSTIGMINE BROMIDIE
CHOLINE FENOFIBRATE	NITAZOXANIDE
CINACALCET	NITROFURANTOIN MONO/ANHYDRS/MACRO CRY
CLONIDINE HCL	NITROFURAZONE
CROMOLYN SODIUM (SODIUM CROMOGLICATE)	NORETHISTERONE / ACETATE
DENATONIUM BENZOATE / SACCHARIDE	PALMITOYLETHANOLAMIDE
DESORATADINE	PERINDOPRIL ERBUMINE / ARGININE
DESOGESTREL	PHENAZONE
DEXKETOPROFEN	PIRFENIDONE
DIMETHYL FUMARATE	PRAMIPEXOLE DI HCL
DILTIAZEM HCL	PREDNISOLONE ACETATE
DIPYRIDAMOLE	PROMETHAZINE HCL/THEOCLATE
DISULFIRAM	PROPYLTHIOURACIL
DOBUTAMINE HCL	RALOXIFENE
DOPAMINE HCL	RUTIN (RUTOSIDE)
DOXYCYCLINE MONO	THALIDOMIDE
DUTASTERIDE	TIMOLOL MALEATE
ESTRADIOL/VALERATE/PHENYL PROP/BENZOATE	TORSEMIDE
ETHINYL ESTRADIOL	TRAZADONE HCL
FINASTERIDE	TRETINOIN 0.1%, 0.04%, 1% , 4%
FLURBIPROFEN SODIUM	TROPICAMIDE
FLUTAMIDE	VERAPAMILE
GADOBUTROL	VITAMINE E 50% POWDER
GATIFLOXACIN	VITAMIN KI (PHYTOMENADIONE)
HYDROQUINONE	XYLOMETAZOLINE
HYDROXYZINE HCL	ZINC BACITRACIN / BACITRACIN
THE ABOVE ALL PRODUCTS AS PER THE LATEST PHARMACOPIEA.	
Note : All above products will not be supplies to countries in which these could be in conflict with existing Patents. The finalresponsibility lies exclusively with the buyer.	